Cardiovascular disease (CVD) is the number one cause of death globally, with an estimated 17.7 million people dying each year. This figure represents approximately 31 percent of all global deaths. This figure is set to increase to over 23.6 million by 2030. These startling statistics highlight the urgent need for better and earlier identification of at risk individuals. This is especially true as in many cases CVD can be prevented with appropriate lifestyle changes. This article elaborates about a novel biomarker for use in CVD risk assessment.
Traditional and routinely run biomarkers include Total Cholesterol, HDL Cholesterol, LDL Cholesterol and Triglycerides. There is however, a growing body of research indicating that further risk assessment biomarkers need to be considered.
These conventional risk assessment markers detect a mere 20 percent of all CVD patients. As the prevalence of CVD continues to rise worldwide, the need for reliable risk markers has never been more important.
Early risk assessment helps to reduce the risk of a cardiac event occurring. Identifying those at highest risk of CVD and ensuring they receive appropriate treatment can prevent premature death. Early risk assessment is particularly important for those people who have one or more risk factors including hypertension, diabetes or hyperlipidaemia.
By 2030, it is estimated that almost 23.6 million people globally will die from CVD, with heart disease and stroke projected to